{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:57:44Z","timestamp":1791928664705,"version":"4.3.4"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]},{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]},{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]},{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]},{"name":"NIH","award":["R01 AG054533"],"award-info":[{"award-number":["R01 AG054533"]}]},{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]},{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]},{"name":"NIH","award":["R01 AG054533"],"award-info":[{"award-number":["R01 AG054533"]}]},{"name":"NIH","award":["R01 AG054533"],"award-info":[{"award-number":["R01 AG054533"]}]},{"name":"NIH","award":["R01 AG054533"],"award-info":[{"award-number":["R01 AG054533"]}]},{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]},{"name":"NIH","award":["R01 MH130591"],"award-info":[{"award-number":["R01 MH130591"]}]},{"name":"NIH","award":["R21 NS097945"],"award-info":[{"award-number":["R21 NS097945"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Norepinephrine (NE) modulates cognitive function, arousal, attention, and responses to novelty and stress, and it also regulates neuroinflammation. We previously demonstrated behavioral and immunomodulatory effects of beta-adrenergic pharmacology in mouse models of Alzheimer\u2019s disease (AD). The current studies were designed to block noradrenergic signaling in 5XFAD mice through (\n                    <jats:bold>1<\/jats:bold>\n                    ) chemogenetic inhibition of the locus coeruleus (LC), (\n                    <jats:bold>2<\/jats:bold>\n                    ) pharmacologic blocking of \u03b2-adrenergic receptors, and (\n                    <jats:bold>3<\/jats:bold>\n                    ) conditional deletion of \u03b21- or \u03b22-adrenergic receptors (adrb1 or adrb2) in microglia.\n                  <\/jats:p>\n                  <jats:p>First, brain-wide AD pathology was mapped in 3D by imaging immunolabeled, cleared 5XFAD brains to assess the overlap between amyloid beta (A\u03b2) pathology, reactive microglia, and the loss of tyrosine hydroxylase (TH) expression in the catecholaminergic system. To examine the effects of inhibiting the LC NE system in the 5XFAD model, inhibitory (Gi) DREADD receptors were expressed specifically in LC NE neurons. LC NE neurons were chronically inhibited through the subcutaneous pump administration of the DREADD agonist clozapine-N-oxide (CNO). Plasma and brains were collected for assessment of neuroinflammation and pathology. A separate cohort of 5XFAD mice was chronically dosed with the beta-adrenergic antagonist propranolol or vehicle and evaluated for behavior, as well as post-mortem neuroinflammation and pathology. Finally, we used 5XFAD mice with conditional deletion of either adrb1 or adrb2 in microglia to assess neuroinflammation and pathology mediated by \u03b2-adrenergic signaling.<\/jats:p>\n                  <jats:p>Using iDISCO+, light sheet fluorescence microscopy, and novel analyses, we detected widespread microgliosis and A\u03b2 pathology, along with modest TH downregulation in fibers across multiple brain regions, in contrast to the spatially limited TH downregulation observed in neurons. Both chemogenetic inhibition of LC adrenergic signaling and pharmacological inhibition of beta-adrenergic receptors potentiated neuroinflammation without altering A\u03b2 pathology. Conditional deletion of adrb1 in microglia did not affect neuroinflammation. Conditional deletion of adrb2 in microglia attenuated inflammation and pathology in females but had no effect in males. Overall, these data support previous observations demonstrating the immunomodulatory effects of beta-adrenergic signaling in the pathophysiology of brain disorders and suggest that adrenergic receptors on cell types other than microglia, such as astrocytes, may mediate some of the disease-modifying effects of \u03b2-adrenergic agonists in the brain.<\/jats:p>","DOI":"10.1186\/s12974-024-03306-1","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:15:47Z","timestamp":1734513347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Impact of noradrenergic inhibition on neuroinflammation and pathophysiology in mouse models of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Andrew K.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heui Hye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Ryskamp","family":"Rijsketic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ciari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Vidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nay Lui","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris D.","family":"Heifets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Shamloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"4","key":"3306_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hipo.22394","volume":"25","author":"SA Thomas","year":"2015","unstructured":"Thomas SA. Neuromodulatory signaling in hippocampus-dependent memory retrieval. Hippocampus. 2015;25(4):415\u201331.","journal-title":"Hippocampus"},{"issue":"1","key":"3306_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.neuron.2012.09.011","volume":"76","author":"SJ Sara","year":"2012","unstructured":"Sara SJ, Bouret S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron. 2012;76(1):130\u201341.","journal-title":"Neuron"},{"issue":"3","key":"3306_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrn2573","volume":"10","author":"SJ Sara","year":"2009","unstructured":"Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10(3):211\u201323.","journal-title":"Nat Rev Neurosci"},{"key":"3306_CR4","doi-asserted-by":"crossref","unstructured":"Matt RA, Martin RS, Evans AK, Gever JR, Vargas GA, Shamloo M et al. Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease. Handb Exp Pharmacol. 2023.","DOI":"10.1007\/164_2023_677"},{"issue":"2","key":"3306_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/jon.12264","volume":"26","author":"S Verclytte","year":"2016","unstructured":"Verclytte S, Lopes R, Lenfant P, Rollin A, Semah F, Leclerc X, et al. Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG-PET in early-onset Alzheimer\u2019s Disease. J Neuroimaging. 2016;26(2):207\u201312.","journal-title":"J Neuroimaging"},{"issue":"3","key":"3306_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 2018;17(3):241\u201350.","journal-title":"Lancet Neurol"},{"key":"3306_CR7","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1038\/ncomms11934","volume":"7","author":"Y Iturria-Medina","year":"2016","unstructured":"Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC. Alzheimer\u2019s Disease Neuroimaging I. early role of vascular dysregulation on late-onset Alzheimer\u2019s disease based on multifactorial data-driven analysis. Nat Commun. 2016;7:11934.","journal-title":"Nat Commun"},{"issue":"2","key":"3306_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12031-012-9742-4","volume":"48","author":"JH Dong","year":"2012","unstructured":"Dong JH, Chen X, Cui M, Yu X, Pang Q, Sun JP. beta2-adrenergic receptor and astrocyte glucose metabolism. J Mol Neurosci. 2012;48(2):456\u201363.","journal-title":"J Mol Neurosci"},{"issue":"13","key":"3306_CR9","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1073\/pnas.0909586107","volume":"107","author":"MT Heneka","year":"2010","unstructured":"Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al. Locus ceruleus controls Alzheimer\u2019s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010;107(13):6058\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3306_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1471-4159.2003.01694.x","volume":"85","author":"MT Heneka","year":"2003","unstructured":"Heneka MT, Gavrilyuk V, Landreth GE, O\u2019Banion MK, Weinberg G, Feinstein DL. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem. 2003;85(2):387\u201398.","journal-title":"J Neurochem"},{"key":"3306_CR11","doi-asserted-by":"publisher","first-page":"105089","DOI":"10.1016\/j.nbd.2020.105089","volume":"146","author":"AK Evans","year":"2020","unstructured":"Evans AK, Ardestani PM, Yi B, Park HH, Lam RK, Shamloo M. Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer\u2019s Disease. Neurobiol Dis. 2020;146:105089.","journal-title":"Neurobiol Dis"},{"issue":"Suppl 2","key":"3306_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/jnc.13447","volume":"139","author":"DL Feinstein","year":"2016","unstructured":"Feinstein DL, Kalinin S, Braun D. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. J Neurochem. 2016;139(Suppl 2):154\u201378.","journal-title":"J Neurochem"},{"key":"3306_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neurobiolaging.2018.10.014","volume":"74","author":"KY Liu","year":"2019","unstructured":"Liu KY, Acosta-Cabronero J, Cardenas-Blanco A, Loane C, Berry AJ, Betts MJ, et al. In vivo visualization of age-related differences in the locus coeruleus. Neurobiol Aging. 2019;74:101\u201311.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"3306_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-020-02248-1","volume":"141","author":"BJ Matchett","year":"2021","unstructured":"Matchett BJ, Grinberg LT, Theofilas P, Murray ME. The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer\u2019s disease. Acta Neuropathol. 2021;141(5):631\u201350.","journal-title":"Acta Neuropathol"},{"key":"3306_CR15","doi-asserted-by":"crossref","unstructured":"Mercan D, Heneka MT. The Contribution of the Locus Coeruleus-Noradrenaline System Degeneration during the Progression of Alzheimer\u2019s Disease. Biology (Basel). 2022;11(12).","DOI":"10.3390\/biology11121822"},{"key":"3306_CR16","doi-asserted-by":"publisher","first-page":"1030609","DOI":"10.3389\/fphar.2022.1030609","volume":"13","author":"AK Evans","year":"2022","unstructured":"Evans AK, Defensor E, Shamloo M. Selective vulnerability of the Locus Coeruleus Noradrenergic System and its role in modulation of Neuroinflammation, Cognition, and Neurodegeneration. Front Pharmacol. 2022;13:1030609.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3306_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-010-0789-4","volume":"121","author":"H Braak","year":"2011","unstructured":"Braak H, Del TK. The pathological process underlying Alzheimer\u2019s disease in individuals under thirty. Acta Neuropathol. 2011;121(2):171\u201381.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"3306_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40478-017-0411-2","volume":"5","author":"SC Kelly","year":"2017","unstructured":"Kelly SC, He B, Perez SE, Ginsberg SD, Mufson EJ, Counts SE. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2017;5(1):8.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"3306_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1212\/WNL.32.2.164","volume":"32","author":"W Bondareff","year":"1982","unstructured":"Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 1982;32(2):164\u20138.","journal-title":"Neurology"},{"issue":"3","key":"3306_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jalz.2016.06.2362","volume":"13","author":"P Theofilas","year":"2017","unstructured":"Theofilas P, Ehrenberg AJ, Dunlop S, Di Lorenzo Alho AT, Nguy A, Leite REP, et al. Locus coeruleus volume and cell population changes during Alzheimer\u2019s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 2017;13(3):236\u201346.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"3306_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.tics.2016.01.001","volume":"20","author":"M Mather","year":"2016","unstructured":"Mather M, Harley CW. The Locus Coeruleus: essential for maintaining cognitive function and the aging brain. Trends Cogn Sci. 2016;20(3):214\u201326.","journal-title":"Trends Cogn Sci"},{"key":"3306_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ynstr.2015.09.002","volume":"2","author":"JA Ross","year":"2015","unstructured":"Ross JA, McGonigle P, Van Bockstaele EJ. Locus Coeruleus, norepinephrine and abeta peptides in Alzheimer\u2019s disease. Neurobiol Stress. 2015;2:73\u201384.","journal-title":"Neurobiol Stress"},{"issue":"4","key":"3306_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tins.2018.01.010","volume":"41","author":"D Weinshenker","year":"2018","unstructured":"Weinshenker D. Long Road to ruin: noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 2018;41(4):211\u201323.","journal-title":"Trends Neurosci"},{"key":"3306_CR24","doi-asserted-by":"crossref","unstructured":"Jacobs HIL, Riphagen JM, Ramakers I, Verhey FRJ. Alzheimer\u2019s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Mol Psychiatry. 2019.","DOI":"10.1038\/s41380-019-0437-x"},{"issue":"6354","key":"3306_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bjornevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357(6354):891\u20138.","journal-title":"Science"},{"issue":"11","key":"3306_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40261-019-00830-4","volume":"39","author":"MS Cepeda","year":"2019","unstructured":"Cepeda MS, Kern DM, Seabrook GR, Lovestone S. Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson\u2019s Drug Discovery. Clin Drug Investig. 2019;39(11):1067\u201375.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"3306_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3233\/JAD-215057","volume":"87","author":"DR Hutten","year":"2022","unstructured":"Hutten DR, Bos JHJ, de Vos S, Hak E. Targeting the Beta-2-Adrenergic receptor and the risk of developing Alzheimer\u2019s Disease: a Retrospective Inception Cohort Study. J Alzheimers Dis. 2022;87(3):1089\u2013101.","journal-title":"J Alzheimers Dis"},{"key":"3306_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/CLEP.S405325","volume":"15","author":"A Paakinaho","year":"2023","unstructured":"Paakinaho A, Tiihonen M, Koskela H, Koponen M, Tiihonen J, Hartikainen S, et al. beta2-Adrenoceptor agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson\u2019s Disease: nested case-control study. Clin Epidemiol. 2023;15:695\u2013705.","journal-title":"Clin Epidemiol"},{"issue":"3","key":"3306_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3233\/JAD-2010-091552","volume":"20","author":"E Duron","year":"2010","unstructured":"Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis. 2010;20(3):903\u201314.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"3306_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/gerona\/60.1.67","volume":"60","author":"I Hajjar","year":"2005","unstructured":"Hajjar I, Catoe H, Sixta S, Boland R, Johnson D, Hirth V, et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol Biol Sci Med Sci. 2005;60(1):67\u201373.","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"1 Pt 1","key":"3306_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1523\/JNEUROSCI.15-01-00152.1995","volume":"15","author":"PW Mantyh","year":"1995","unstructured":"Mantyh PW, Rogers SD, Allen CJ, Catton MD, Ghilardi JR, Levin LA, et al. Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous system in the rat, rabbit, and human. J Neurosci. 1995;15(1 Pt 1):152\u201364.","journal-title":"J Neurosci"},{"issue":"1","key":"3306_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0006-8993(86)91112-1","volume":"370","author":"R Cash","year":"1986","unstructured":"Cash R, Raisman R, Lanfumey L, Ploska A, Agid Y. Cellular localization of adrenergic receptors in rat and human brain. Brain Res. 1986;370(1):127\u201335.","journal-title":"Brain Res"},{"key":"3306_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.neuropharm.2017.01.010","volume":"116","author":"PM Ardestani","year":"2017","unstructured":"Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer\u2019s disease using a biased and selective beta-1 adrenergic receptor partial agonist. Neuropharmacology. 2017;116:371\u201386.","journal-title":"Neuropharmacology"},{"key":"3306_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neurobiolaging.2021.06.012","volume":"106","author":"AK Evans","year":"2021","unstructured":"Evans AK, Park HH, Saw NL, Singhal K, Ogawa G, Leib RD, et al. Age-related neuroinflammation and pathology in the locus coeruleus and hippocampus: beta-adrenergic antagonists exacerbate impairment of learning and memory in aged mice. Neurobiol Aging. 2021;106:241\u201356.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"3306_CR35","doi-asserted-by":"publisher","first-page":"e0180319","DOI":"10.1371\/journal.pone.0180319","volume":"12","author":"B Yi","year":"2017","unstructured":"Yi B, Jahangir A, Evans AK, Briggs D, Ravina K, Ernest J, et al. Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. PLoS ONE. 2017;12(7):e0180319.","journal-title":"PLoS ONE"},{"issue":"5","key":"3306_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/acn3.57","volume":"1","author":"L Coutellier","year":"2014","unstructured":"Coutellier L, Ardestani PM, Shamloo M. beta1-adrenergic receptor activation enhances memory in Alzheimer\u2019s disease model. Ann Clin Transl Neurol. 2014;1(5):348\u201360.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"3306_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.nbd.2011.04.011","volume":"43","author":"M Faizi","year":"2011","unstructured":"Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis. 2011;43(2):397\u2013413.","journal-title":"Neurobiol Dis"},{"issue":"26","key":"3306_CR38","doi-asserted-by":"publisher","first-page":"8845","DOI":"10.1523\/JNEUROSCI.4027-13.2014","volume":"34","author":"MP Kummer","year":"2014","unstructured":"Kummer MP, Hammerschmidt T, Martinez A, Terwel D, Eichele G, Witten A, et al. Ear2 deletion causes early memory and learning deficits in APP\/PS1 mice. J Neurosci. 2014;34(26):8845\u201354.","journal-title":"J Neurosci"},{"issue":"5","key":"3306_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.biopsych.2012.06.013","volume":"73","author":"T Hammerschmidt","year":"2013","unstructured":"Hammerschmidt T, Kummer MP, Terwel D, Martinez A, Gorji A, Pape HC, et al. Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP\/PS1 mice. Biol Psychiatry. 2013;73(5):454\u201363.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"3306_CR40","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.neurobiolaging.2006.06.003","volume":"28","author":"S Kalinin","year":"2007","unstructured":"Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, et al. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer\u2019s disease. Neurobiol Aging. 2007;28(8):1206\u201314.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"3306_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1523\/JNEUROSCI.4236-05.2006","volume":"26","author":"MT Heneka","year":"2006","unstructured":"Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006;26(5):1343\u201354.","journal-title":"J Neurosci"},{"issue":"40","key":"3306_CR42","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129\u201340.","journal-title":"J Neurosci"},{"key":"3306_CR43","doi-asserted-by":"crossref","unstructured":"Evans AK, Saw NL, Woods CE, Vidano LM, Blumenfeld S, Lam RK et al. Impact of high-fat diet on cognitive behavior and central and systemic inflammation with aging and sex differences in mice. Brain Behav Immun. 2024.","DOI":"10.1016\/j.bbi.2024.02.025"},{"issue":"2","key":"3306_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/brb3.41","volume":"2","author":"M Faizi","year":"2012","unstructured":"Faizi M, Bader PL, Saw N, Nguyen TV, Beraki S, Wyss-Coray T, et al. Thy1-hAPP(Lond\/Swe+) mouse model of Alzheimer\u2019s disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2012;2(2):142\u201354.","journal-title":"Brain Behav"},{"issue":"3","key":"3306_CR45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nmeth1019","volume":"4","author":"JE Elias","year":"2007","unstructured":"Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007;4(3):207\u201314.","journal-title":"Nat Methods"},{"key":"3306_CR46","unstructured":"Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. second ed. San Diego: Academic Press; 2001 2001."},{"issue":"4","key":"3306_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2014.10.010","volume":"159","author":"N Renier","year":"2014","unstructured":"Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell. 2014;159(4):896\u2013910.","journal-title":"Cell"},{"key":"3306_CR48","doi-asserted-by":"crossref","unstructured":"Rijsketic DR, Casey AB, Barbosa DAN, Zhang X, Hietamies TM, Ramirez-Ovalle G et al. UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacology. 2023;48(12):1798\u20131807.","DOI":"10.1038\/s41386-023-01613-4"},{"issue":"1","key":"3306_CR49","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1038\/s41467-019-13374-0","volume":"10","author":"M Goubran","year":"2019","unstructured":"Goubran M, Leuze C, Hsueh B, Aswendt M, Ye L, Tian Q, et al. Multimodal image registration and connectivity analysis for integration of connectomic data from microscopy to MRI. Nat Commun. 2019;10(1):5504.","journal-title":"Nat Commun"},{"issue":"3","key":"3306_CR50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12021-020-09490-8","volume":"19","author":"J Perens","year":"2021","unstructured":"Perens J, Salinas CG, Skytte JL, Roostalu U, Dahl AB, Dyrby TB, et al. An optimized mouse brain Atlas for Automated Mapping and quantification of neuronal activity using iDISCO\u2009+\u2009and light sheet fluorescence Microscopy. Neuroinformatics. 2021;19(3):433\u201346.","journal-title":"Neuroinformatics"},{"key":"3306_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","volume":"73","author":"RL Wasserstein","year":"2019","unstructured":"Wasserstein RL, Schirm AL, Lazar NA. Moving to a World Beyond p\u2009<\u20090.05. Am Stat. 2019;73:1\u201319.","journal-title":"Am Stat"},{"issue":"7748","key":"3306_CR52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","volume":"567","author":"V Amrhein","year":"2019","unstructured":"Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305\u20137.","journal-title":"Nature"},{"issue":"4","key":"3306_CR53","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.celrep.2016.06.060","volume":"16","author":"T Liebmann","year":"2016","unstructured":"Liebmann T, Renier N, Bettayeb K, Greengard P, Tessier-Lavigne M, Flajolet M. Three-dimensional study of Alzheimer\u2019s Disease Hallmarks using the iDISCO Clearing Method. Cell Rep. 2016;16(4):1138\u201352.","journal-title":"Cell Rep"},{"key":"3306_CR54","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.nbd.2019.03.010","volume":"127","author":"JR Detrez","year":"2019","unstructured":"Detrez JR, Maurin H, Van Kolen K, Willems R, Colombelli J, Lechat B, et al. Regional vulnerability and spreading of hyperphosphorylated tau in seeded mouse brain. Neurobiol Dis. 2019;127:398\u2013409.","journal-title":"Neurobiol Dis"},{"key":"3306_CR55","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s42003-019-0599-8","volume":"2","author":"R Gail Canter","year":"2019","unstructured":"Gail Canter R, Huang WC, Choi H, Wang J, Ashley Watson L, Yao CG, et al. 3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice. Commun Biol. 2019;2:360.","journal-title":"Commun Biol"},{"key":"3306_CR56","doi-asserted-by":"crossref","unstructured":"Lee SH, Son HJ. Second Wave, Late-Stage Neuroinflammation in Cleared Brains of Aged 5xFAD Alzheimer\u2019s Mice Detected by Macrolaser Light Sheet Microscopy Imaging. Int J Mol Sci. 2023;24(23).","DOI":"10.3390\/ijms242317058"},{"key":"3306_CR57","doi-asserted-by":"publisher","first-page":"1345692","DOI":"10.3389\/fncir.2024.1345692","volume":"18","author":"P Gao","year":"2024","unstructured":"Gao P, Rivera M, Lin X, Holmes TC, Zhao H, Xu X. Immunolabeling-compatible PEGASOS tissue clearing for high-resolution whole mouse brain imaging. Front Neural Circuits. 2024;18:1345692.","journal-title":"Front Neural Circuits"},{"key":"3306_CR58","doi-asserted-by":"crossref","unstructured":"Rijsketic DR, Casey AB, Barbosa DAN, Zhang X, Hietamies TM, Ramirez-Ovalle G et al. UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. bioRxiv. 2023.","DOI":"10.1101\/2023.02.19.528997"},{"key":"3306_CR59","doi-asserted-by":"crossref","unstructured":"Baek S, Jang J, Jung HJ, Lee H, Choe Y. Advanced Immunolabeling Method for Optical Volumetric Imaging Reveals Dystrophic Neurites of Dopaminergic Neurons in Alzheimer\u2019s Disease Mouse Brain. Mol Neurobiol. 2023.","DOI":"10.1007\/s12035-023-03823-9"},{"key":"3306_CR60","doi-asserted-by":"publisher","first-page":"914359","DOI":"10.3389\/fnana.2022.914359","volume":"16","author":"J Francis-Oliveira","year":"2022","unstructured":"Francis-Oliveira J, Leitzel O, Niwa M. Are the anterior and mid-cingulate cortices distinct in rodents? Front Neuroanat. 2022;16:914359.","journal-title":"Front Neuroanat"},{"issue":"5","key":"3306_CR61","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0197-0186(02)00049-9","volume":"41","author":"DL Feinstein","year":"2002","unstructured":"Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int. 2002;41(5):357\u201365.","journal-title":"Neurochem Int"},{"issue":"4","key":"3306_CR62","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.neuint.2010.02.001","volume":"57","author":"D Jardanhazi-Kurutz","year":"2010","unstructured":"Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, et al. Induced LC degeneration in APP\/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int. 2010;57(4):375\u201382.","journal-title":"Neurochem Int"},{"issue":"4","key":"3306_CR63","doi-asserted-by":"publisher","first-page":"e92325","DOI":"10.1371\/journal.pone.0092325","volume":"9","author":"SS Choi","year":"2014","unstructured":"Choi SS, Lee HJ, Lim I, Satoh J, Kim SU. Human astrocytes: secretome profiles of cytokines and chemokines. PLoS ONE. 2014;9(4):e92325.","journal-title":"PLoS ONE"},{"issue":"1","key":"3306_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0002-9440(10)65542-3","volume":"153","author":"MQ Xia","year":"1998","unstructured":"Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer\u2019s disease brains. Am J Pathol. 1998;153(1):31\u20137.","journal-title":"Am J Pathol"},{"issue":"Pt 3","key":"3306_CR65","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/brain\/aws330","volume":"136","author":"S Imai","year":"2013","unstructured":"Imai S, Ikegami D, Yamashita A, Shimizu T, Narita M, Niikura K, et al. Epigenetic transcriptional activation of monocyte chemotactic protein 3 contributes to long-lasting neuropathic pain. Brain. 2013;136(Pt 3):828\u201343.","journal-title":"Brain"},{"issue":"2","key":"3306_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.20041674","volume":"201","author":"M Krumbholz","year":"2005","unstructured":"Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195\u2013200.","journal-title":"J Exp Med"},{"key":"3306_CR67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bbi.2020.11.033","volume":"92","author":"X Pan","year":"2021","unstructured":"Pan X, Kaminga AC, Wu Wen S, Liu A. Chemokines in post-traumatic stress disorder: a network meta-analysis. Brain Behav Immun. 2021;92:115\u201326.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"3306_CR68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/mp.2017.205","volume":"23","author":"SP Leighton","year":"2018","unstructured":"Leighton SP, Nerurkar L, Krishnadas R, Johnman C, Graham GJ, Cavanagh J. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2018;23(1):48\u201358.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"3306_CR69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11011-020-00648-6","volume":"36","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, Honarmand K, Taheri M. A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. Metab Brain Dis. 2021;36(3):375\u2013406.","journal-title":"Metab Brain Dis"},{"issue":"2","key":"3306_CR70","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.psyneuen.2009.06.007","volume":"35","author":"SM Lehto","year":"2010","unstructured":"Lehto SM, Niskanen L, Herzig KH, Tolmunen T, Huotari A, Viinamaki H, et al. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology. 2010;35(2):226\u201332.","journal-title":"Psychoneuroendocrinology"},{"issue":"2\u20133","key":"3306_CR71","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.psychres.2009.02.007","volume":"176","author":"AM Geppert","year":"2010","unstructured":"Geppert AM, Losy J, Przedpelska-Ober E, Kozubski W. CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer\u2019s disease. Psychiatry Res. 2010;176(2\u20133):261\u20134.","journal-title":"Psychiatry Res"},{"issue":"2","key":"3306_CR72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3988\/jcn.2008.4.2.84","volume":"4","author":"C Choi","year":"2008","unstructured":"Choi C, Jeong JH, Jang JS, Choi K, Lee J, Kwon J, et al. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer\u2019s disease by color-coded bead technology. J Clin Neurol. 2008;4(2):84\u20138.","journal-title":"J Clin Neurol"},{"issue":"11","key":"3306_CR73","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/mp.2015.131","volume":"20","author":"MA Lalli","year":"2015","unstructured":"Lalli MA, Bettcher BM, Arcila ML, Garcia G, Guzman C, Madrigal L, et al. Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer\u2019s disease. Mol Psychiatry. 2015;20(11):1294\u2013300.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"3306_CR74","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1750-3639.2008.00188.x","volume":"19","author":"A Sokolova","year":"2009","unstructured":"Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer\u2019s disease. Brain Pathol. 2009;19(3):392\u20138.","journal-title":"Brain Pathol"},{"key":"3306_CR75","doi-asserted-by":"crossref","unstructured":"Kimura A, Yoshikura N, Hayashi Y, Inuzuka T, Cerebrospinal Fluid C-C, Motif Chemokine. Ligand 2 correlates with brain atrophy and cognitive impairment in Alzheimer\u2019s Disease. J Alzheimers Dis. 2018;61(2):581\u20138.","DOI":"10.3233\/JAD-170519"},{"issue":"12","key":"3306_CR76","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.neurobiolaging.2005.10.007","volume":"27","author":"D Galimberti","year":"2006","unstructured":"Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B, et al. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer\u2019s disease. Neurobiol Aging. 2006;27(12):1763\u20138.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"3306_CR77","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359\u201362.","journal-title":"Nat Med"},{"issue":"1","key":"3306_CR78","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/mds.29257","volume":"38","author":"M Bartl","year":"2023","unstructured":"Bartl M, Dakna M, Schade S, Otte B, Wicke T, Lang E, et al. Blood markers of inflammation, neurodegeneration, and Cardiovascular Risk in Early Parkinson\u2019s Disease. Mov Disord. 2023;38(1):68\u201381.","journal-title":"Mov Disord"},{"issue":"Pt 6","key":"3306_CR79","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/brain\/awn077","volume":"131","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, Kumpfel T, Pellkofer H, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 2008;131(Pt 6):1455\u201363.","journal-title":"Brain"},{"issue":"7","key":"3306_CR80","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1352458511398887","volume":"17","author":"S Ragheb","year":"2011","unstructured":"Ragheb S, Li Y, Simon K, VanHaerents S, Galimberti D, De Riz M, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011;17(7):819\u201329.","journal-title":"Mult Scler"},{"issue":"2","key":"3306_CR81","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/(SICI)1098-1136(199606)17:2<133::AID-GLIA5>3.0.CO;2-3","volume":"17","author":"CD Paspalas","year":"1996","unstructured":"Paspalas CD, Papadopoulos GC. Ultrastructural relationships between noradrenergic nerve fibers and non-neuronal elements in the rat cerebral cortex. Glia. 1996;17(2):133\u201346.","journal-title":"Glia"},{"issue":"4\u20135","key":"3306_CR82","first-page":"315","volume":"60","author":"D Morin","year":"1997","unstructured":"Morin D, Sapena R, Zini R, Onteniente B, Tillement JP. Characterization of beta-adrenergic receptors of freshly isolated astrocytes and neurons from rat brain. Life Sci. 1997;60(4\u20135):315\u201324.","journal-title":"Life Sci"},{"issue":"3","key":"3306_CR83","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1152\/japplphysiol.00954.2005","volume":"100","author":"E Hamel","year":"2006","unstructured":"Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol (1985). 2006;100(3):1059\u201364.","journal-title":"J Appl Physiol (1985)"},{"issue":"11","key":"3306_CR84","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nn2003","volume":"10","author":"C Iadecola","year":"2007","unstructured":"Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007;10(11):1369\u201376.","journal-title":"Nat Neurosci"},{"issue":"10","key":"3306_CR85","first-page":"1625","volume":"46","author":"A Drzezga","year":"2005","unstructured":"Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46(10):1625\u201332.","journal-title":"J Nucl Med"},{"issue":"1","key":"3306_CR86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s44192-023-00050-5","volume":"3","author":"ER Bowen","year":"2023","unstructured":"Bowen ER, DiGiacomo P, Fraser HP, Guttenplan K, Smith BAH, Heberling ML, et al. Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease. Discov Ment Health. 2023;3(1):27.","journal-title":"Discov Ment Health"},{"issue":"6","key":"3306_CR87","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, et al. Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat Neurosci. 2020;23(6):701\u20136.","journal-title":"Nat Neurosci"},{"issue":"8","key":"3306_CR88","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457\u201370.","journal-title":"Nat Rev Neurol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-024-03306-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:14:24Z","timestamp":1734516864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-024-03306-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3306"],"URL":"https:\/\/doi.org\/10.1186\/s12974-024-03306-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5328229\/v1","asserted-by":"object"}]},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MS is a shareholder and founder of CuraSen Therapeutics, a company developing adrenergic drugs for the treatment of neurodegenerative disease. AKE is a shareholder of CuraSen Therapeutics. However, this work was initiated and carried out independently from CuraSen Therapeutics and was not designed, initiated, or funded by CuraSen Therapeutics. BDH is on the scientific advisory boards of Journey Clinical and Osmind, and is a paid consultant to Arcadia Medicine, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}